Two-year-old girl dies from bird flu after eating raw chicken
A two-year-old girl in southern India died from bird flu after eating raw chicken, the first fatality linked to the H5N1 strain since 2021.
The toddler, from Palnadu district in Andhra Pradesh state, died on 15 March after developing fever, breathing difficulties and diarrhoea.
Authorities said the child contracted the virus after consuming raw chicken. It was not clear if she had been deliberately fed the meat or accidentally eaten it.
She was initially admitted to a local health centre but taken to a city hospital on 4 March after her condition deteriorated.
A sample test for avian influenza of H5N1 strain at the hospital returned positive, and the patient eventually died despite receiving appropriate medical treatment, the hospital said in a statement.
Damodar Naidu, director of animal husbandry in Andhra Pradesh, said the child was admitted to hospital two-three days after consuming the raw chicken, according to Down To Earth.
Following the death, he said authorities conducted physical surveillance of all poultry farms in the region, but found no signs of bird flu among poultry.
'There were isolated outbreaks in February but effective control measures were implemented promptly,' Mr Naidu said. 'No traces of the virus were found in the surveyed areas.'
However, he urged the public to consume only properly cooked chicken and eggs. 'Poultry should be cooked to at least 70C. Eggs should be boiled and not eaten raw,' he said.
No one in the girl's family tested positive for the flu.
The federal health ministry deployed an outbreak response team to Andhra Pradesh to assist in the case.
Bird flu is caused by a virus that infects birds and sometimes foxes, otters and seals. It rarely infects humans, but a major strain known as H5N1 has caused global health concern.
Only five cases of H5N1 and H9N2 strains have been detected in India over the past five years, the Andhra government reported in a statement.
An 11-year-old in the northern Haryana state died in the last confirmed human fatality from H5N1 in 2021. The boy died after developing multiorgan dysfunction.
According to the WHO, the first human outbreak of the virus took place in 1997 in Hong Kong. There have been a little more than 900 known cases globally since 2003 with nearly 50 per cent proving fatal.
in an area where the disease had been confirmed in captive birds.
Last year, the strain spread rapidly in dairy cow herds in the US and the US Centres for Disease Control described it as an "ongoing multi-state outbreak".
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
4 hours ago
- Telegraph
How vaccine fears and summer holidays could trigger a measles surge
As the June heatwave begins and families prepare for a summer of festivals and flying off abroad, experts are warning that thousands may return home this year with an unwanted holiday souvenir. Measles – the highly infectious but preventable disease from the past – is making a concerning comeback. Already, a number of popular destinations – including France, Spain and Italy – have seen 'large' outbreaks, according to the UK Health Security Agency (UKHSA). Analysis by WHO Europe and Unicef reported 127,350 measles cases in the European region for 2024, double the number of cases reported for 2023. It is also the highest number since 1997. It's a similar story across the pond. Canada, which only recorded an average of 91 measles cases annually from 1998 to 2024, has 2,885 confirmed cases already this year. Meanwhile, there were more measles cases in the US during the first three months of 2025 than in all of 2024, according to the Centres for Disease Control and Prevention. 'It's essential that everyone, particularly parents of young children, check all family members are up to date with two MMR doses, especially if you are travelling this summer for holidays or visiting family,' says Dr Vanessa Saliba, a consultant epidemiologist at UKHSA. 'Measles cases are picking up again in England and outbreaks are happening in Europe and many countries with close links to the UK. 'Measles spreads very easily and can be a nasty disease, leading to complications like ear and chest infections and inflammation of the brain with some children tragically ending up in hospital and suffering life-long consequences. Nobody wants this for their child and it's not something you want to experience when away on holiday.' While cases are still lower in the UK than they were in 2024, experts are also worried that unvaccinated people could contract the disease at large-scale events such as Glastonbury – which starts next week. 'Festivals are the perfect place for measles to spread,' says Dr Alasdair Wood, a consultant in health protection at UKHSA South West. 'We want festival-goers to enjoy their time at Glastonbury and other festivals this year. Being aware of the current health risks will help those attending enjoy their time as much as possible. If you're not fully vaccinated against measles, mumps and rubella, please contact your GP to see if you can get an appointment before coming to the festival.' Vaccine hesitancy and the declining MMR vaccination rates – only 85 per cent of UK children are receiving two doses, well below the 95 per cent needed for herd immunity – may well be the reason why a surge in measles is being predicted later this year. Dr Hana Patel, a GP, says that although she hasn't seen any cases of measles this year so far in her surgery in south-east London, like most health professionals, she's concerned that the pandemic as well as other factors are to blame for the lack of vaccinations in some parts of the UK. 'There have always been some communities who are vaccine hesitant – there is evidence that traveller communities don't have access to the same information most people do, or patients from particular areas from Europe, where they don't have a vaccine schedule, are two examples,' she says. 'But after Covid, I've noticed more people – even some doctors – who seem quite complacent about vaccines. 'It's not always a family's fault. If you have a transient population, perhaps a family in temporary accommodation who are then moved to another area, they might miss their letter or appointment. Or then they will get an appointment and then forget about it because it's not on everyone's mind all the time. It's really important to find out the challenges in each particular area and target them with specific help. 'Other parents may not understand that it's not just one vaccination but you need two to be fully protected. Children in larger families may also be at risk because parents think one child has had it and so they think that protects the others or they can't remember if the others have had it. Speaking a different language may be another factor. 'I really hope that more people get the vaccine done, because long-term consequences such as meningitis and hearing loss, are incredibly serious. We also have to remember the risks to pregnant women of being exposed to measles too (contracting measles can lead to severe complications with pregnancy and birth). It's more than just the child who has been vaccinated, it's the people around them too.' Dr Naveed Asif, a GP from the London General Practice, says he has encountered a diverse spectrum of patients who have been influenced by the misinformation surrounding vaccines. 'One notable instance involved a well-educated couple who meticulously researched every decision they make regarding their children's health,' he says. 'They came to me with a palpable sense of uncertainty after reading a negative article about the MMR vaccine. Despite the wealth of positive data supporting its safety and efficacy, they were fixated on that one negative report. 'I've also treated patients from backgrounds where traditional beliefs about health are prevalent. For example, families from South Asian communities often rely heavily on parental advice and anecdotal experiences. They might argue that they've never needed vaccines in their lives and feel confident in their decision to forgo them. This reliance on peer opinion can lead to a strong sense of community validation, but it can also perpetuate hesitancy about vaccinations. 'From my personal experience, I often see sick children presenting to their GP first, and I have encountered significantly unwell children whose parents have chosen not to vaccinate. These families often find themselves reliant on more invasive, distressing and intensive resources to support their child's illness. I firmly believe that exposing children to vaccines early, rather than keeping them unprotected, is more likely to build immunity and contribute to healthier, stronger adults overall.' But vaccine hesitancy is not the only factor. Although the figures for measles were low during the Covid pandemic, the lockdowns appear to have exacerbated the current increase in measles figures, with over 1.8 million infants in the WHO European region missing their vaccinations between 2020 and 2022. England had already experienced 2,911 laboratory-confirmed measles cases in 2024, the highest number of cases recorded annually since 2012. One young person was confirmed to have died in the UK last year of the disease. 'We have seen a steady decline in vaccination coverage for children over the past 10 years and we now find ourselves in a situation where the UK does not meet the WHO target of 95 per cent coverage for any routine childhood immunisations,' says Dr Helen Stewart, the officer for health improvement at the Royal College of Paediatrics and Child Health. 'The result of this trend is being felt already, with measles outbreaks occurring across the UK, increasing cases of whooping cough and poliovirus being found in sewage samples in London. 'Because the MMR vaccine has been so successful in preventing outbreaks, many parents and caregivers today have never witnessed the sometimes devastating impact measles can have on children and babies. Measles is one of the more contagious diseases – more transmissible than even Covid – and poses a serious threat, especially to children under the age of five. 'Paediatricians are particularly concerned about current and potential outbreaks in the UK, especially during the upcoming winter period. This is already an extremely tough time for health care professionals, with high surges in respiratory syncytial virus (RSV) and influenza, as well as circulating Covid and group A streptococcus (GAS). To have another highly contagious, dangerous and preventable disease, making children sick, would be disastrous. Not only could it put other young patients at serious risk, it could also add further pressure to paediatric wards. 'We understand that vaccine hesitancy may be an issue in some instances, but evidence shows that accessibility and availability of health appointments plays a huge role in low uptake. We urge the UK Government to take forward the commitments of the NHS's vaccine strategy and work towards reversing this dangerous trend.' Six decades ago, up to more than half a million people in the UK could be affected by measles each year, and around 100 people would die annually. Author Roald Dahl's seven-year-old daughter was one such victim, dying of complications from the disease in 1962. Thousands were left with respiratory, brain or hearing problems. But the MMR vaccine changed everything. Introduced in 1968, it's thought to have prevented over 20 million measles cases and 4,500 deaths in the UK. When offered to all children in 1988 (and the second dose MMR vaccine was brought in for preschoolers in 1996), the number of cases in the UK fell dramatically. So much so that in 2017, WHO confirmed that the UK had achieved 'measles elimination status', something the US had already achieved in 2000. Despite the UK losing this status shortly afterwards, it regained it again in 2021 after the Covid pandemic. Yet now, doctors are facing real fears that it has taken a foothold once again. 'The challenge is not anecdotal, it is very real,' says Dr Benjamin Kasstan-Dabush of the London School of Hygiene and Tropical Medicine. 'There has been a global rise in measles cases, and two unvaccinated children died from measles in Texas this year, reminding us of just how dangerous this preventable disease is. 'High vaccination coverage helps to prevent the spread of disease, but rates are just not as high as they need to be. It is likely that the number of confirmed cases of measles does not reflect the actual burden of illness. 'This is particularly worrying because a child infected with measles can deteriorate rapidly, and there is always a risk of them developing encephalitis (inflammation of the brain). So, we should all be concerned about a predicted surge in measles cases.' Since January this year, 420 lab-confirmed measles cases have been reported in England, with London reporting almost half of all cases in the past four weeks. Outside the capital, Bristol has seen the highest number of cases, with 47 so far this year, followed by Leeds (29) and Essex (22). A number of other regions are also reporting outbreaks, with 25 per cent of cases in the North West, and 11 per cent in the West Midlands. Earlier this month, UKHSA published its monthly update showing there were 109 confirmed cases in April and 86 so far in May – most have been in unvaccinated children aged 10 years and under. 'We have seen a small increase in the number of measles cases in Birmingham over recent weeks,' says Dr Clara Day, the chief medical officer for NHS Birmingham and Solihull. 'We know how easy it is for viruses like this to spread within our communities, especially where we know there is a high number of unvaccinated people. 'Unfortunately we know that misinformation surrounding the MMR immunisation is prevalent, but it is safe, effective and the only protection we have against these illnesses. Measles in particular can be deadly in the most serious of cases, so I would encourage all parents to make informed decisions about whether to get their child immunised.'
The Independent
a day ago
- The Independent
Painful symptom of latest Covid variant identified
The NB.1.8.1, or "Nimbus," Covid variant is now nearly the most prevalent omicron lineage tracked by the CDC. A notable symptom associated with Nimbus is an incredibly painful "razor blade throat," though other symptoms are typical of Covid infection. Experts state that despite its rapid spread, the Nimbus variant does not appear to be more severe than previous strains. The variant's quick transmissibility is attributed to genetic mutations that allow it to bind easily to human cells. The World Health Organization has designated Nimbus as a "variant under monitoring" and considers the global public health risk to be low, with current vaccines expected to remain effective.
The Independent
a day ago
- The Independent
US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need
US medicines regulator the Food and Drug Administration (FDA) has approved a groundbreaking HIV prevention jab hailed as having the potential to quell the Aids pandemic. But the moment has been overshadowed by the spectre of aid cuts, placing in doubt whether this breakthrough injection – lenacapavir – will get to the people who need it most. Lenacapavir given in a twice-yearly injection stops HIV from replicating, protecting close to 100 per cent of people from developing the virus if they are exposed to it. This approval is one of the last crucial steps to getting the drug, branded Yeztugo, out to patients. Although the FDA's approval only applies to US patients, the World Health Organization (WHO) said it paved the way for its own recommendation of the drug and for approval in other countries. Director of WHO's Global HIV, Hepatitis and STI Programmes, Dr Meg Doherty described it as a 'regulatory milestone' adding: 'We are working with partners and national authorities to ensure lenacapavir reaches people who need it most – quickly, safely and equitably.' Researchers have raised concerns that, amid aid cuts, the jab will be too expensive to be taken up by lower-income countries. Gilead – the drugs company producing lencapavir – did not make public the cost of each dose to global funders but it announced a US price of $28,218 per year for each patient. 'If this game-changing medicine remains unaffordable, it will change nothing,' said Winnie Byanyima, executive director of the United Nations' Aids agency, UNAIDS. She called the approval of lenacapavir a 'breakthrough moment' adding the jab, 'could be the tool we need to bring new infections under control – but only if it is priced affordably and made available to everyone who could benefit. ' UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is beyond comprehension how Gilead can justify a price of $28,218.' Dr Andrew Hill, a pharmacology research fellow at the University of Liverpool, worked on the research which found lenacapavir could be provided for as little as $25, including a 30 per cent profit margin. 'Scientifically, it's a great moment that we have a drug which has been judged to be safe and efficacious by a leading regulatory authority in the world,'' he said. 'Public health-wise and in terms of the epidemic, it's tragic because the drug is so expensive that it's not going to get used'. It is also unlikely to be affordable in the UK, he said, despite government promises to end new cases of HIV in England by 2030. A Gilead spokesperson said, 'Yeztugo is priced in line with existing branded PrEP [pre-exposure prophylaxis] options. We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage in the US. 'We're taking unprecedented actions with urgency to plan for access to lenacapavir for PrEP globally—particularly in low- and lower-middle-income countries where the need is greatest.' Gilead signed agreements with six pharmaceutical companies in India, Pakistan, Egypt, and the US to allow them to make generic versions of the drug in order to increase supply and drive down the cost of the jab. This will take some time. Gilead also agreed to sell enough doses of the jab to protect at least two million people over three years in lower-income countries. These would be paid for by global funders led by the US President's Emergency Plan for Aids Relief (Pepfar) and the Global Fund to Fight Aids, Tuberculosis and Malaria. However, The Independent reported earlier in the month that these doses are now at risk because of US funding cuts. A significant chunk of the money to fund the doses of lenacapavir was set to come from the US-led global Aids response programme, Pepfar, as well as the Global Fund whose biggest donor was the US. This funding is now uncertain. Figures previously reported by The Independent suggest President Trump's slashing of foreign aid has derailed the projected end of the Aids pandemic and could lead to four million extra deaths by 2030. 'It does feel like this thing that could help us end the epidemic sooner is suddenly receding in the chaos,' said Prof Linda-Gail Bekker, whose trial demonstrated lenacapavir's effectiveness. The aid-funded doses are thought to cost much less than the US list price of almost $30k but still roughly five times more expensive than Dr Hill believes is necessary. And they are in an initial pilot phase, he said: 'We need to get into a different level where we're giving lenacapavir to tens of millions of people'. This is even more important as aid cuts are slashing the HIV prevention budgets of governments across Africa, he said. 'We're in this crazy position where we have a brand new highly effective vaccine-like drug and actually we will probably see the epidemic get worse over the next four years.'
